Abstract
Objective: Mast cells found to be an important contributor to inflammation, obesity, diabetes and atherosclerosis. We evaluate the ability of ketotifen to reduce cardiovascular risk in patient with type 2 diabetes millets (T2DM). Method: In a randomized controlled study we recruited forty eight patients with T2DM from Internal Medicine Department at Tanta University Hospital, Egypt. They were classified in to three groups. Group 1: received glimepiride (GL) 3 mg/day alone; group 2: received GL 3 mg/day +ketotifen 1 mg once daily; group 3: received GL 3 mg/day +ketotifen 1 mg twice daily. Fasting blood samples were obtained before and 12 weeks after treatment for biochemical analysis of IL-6 and lipid profile with subsequent calculation of Castelli index 1 and atherogenic coefficient. Body mass index was also calculated for all patients. Data were analyzed by paired student's t-test and one way analysis of variance, p<0.05 was considered statistically significant. Results: The obtained data suggested that ketotifen in its twice daily dose significantly improves lipid profile and decreases IL-6 level, castelli index 1 and atherogenic coefficient. Conclusions: Mast cell stabilization with ketotifen can decrease the risk of diabetes associated cardiovascular complications
Highlights
Patients with DM will present with microvascular or macrovascular degeneration [1]
No clear data was reported upon the effect of mast cell stabilizers on human, so the present study was designed to investigate the ability of ketotifen to decrease cardiovascular risk (CV) in patients with type 2 diabetes millets (T2DM)
Lipid panel: Plasma was used for determination of lipid profiles including total cholesterol (TC) which was measured by enzymatic colorimetric method [9], triglycerides (TGs) which was any significant difference among the three groups at base line and after 12 weeks
Summary
Mast cells found to be an important contributor to inflammation, obesity, diabetes and atherosclerosis. Method: In a randomized controlled study we recruited forty eight patients with T2DM from Internal Medicine Department at Tanta University Hospital, Egypt. Results: The obtained data suggested that ketotifen in its twice daily dose significantly improves lipid profile and decreases IL-6 level, castelli index 1 and atherogenic coefficient. Conclusions: Mast cell stabilization with ketotifen can decrease the risk of diabetes associated cardiovascular complications. The most important finding of recent studies is that mast cell stabilization with cromolyn or ketotifen reduces body weight gain and improves glucose and insulin tolerance in mice without noticeable toxicity [7]. No clear data was reported upon the effect of mast cell stabilizers on human, so the present study was designed to investigate the ability of ketotifen to decrease cardiovascular risk (CV) in patients with T2DM
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
